Crossmark

Cognitive training for children and adolescents with fragile X syndrome: a randomized controlled trial of Cogmed

Crossref DOI link: https://doi.org/10.1186/s11689-019-9264-2

Published Online: 2019-04-15

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hessl, David https://orcid.org/0000-0002-3460-9805
Schweitzer, Julie B.

Nguyen, Danh V.

McLennan, Yingratana A.

Johnston, Cindy

Shickman, Ryan

Chen, Yanjun
License Information

Text and Data Mining valid from 2019-04-15
More Information

Article History

Received: 14 November 2018

Accepted: 20 March 2019

First Online: 15 April 2019

Ethics approval and consent to participate

: This study was approved by the Institutional Review Board at University of California, Davis, and all participants provided informed consent.

: Not applicable.

: Dr. Hessl has received compensation for consulting to Novartis, Roche, Zynerba, Autifony, and Ovid pharmaceuticals regarding fragile X clinical trials. The Pearson Corporation provided Cogmed licenses but had no role in the conduct, analyses, or reporting of the study. The other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.